Modified natural killer cells and natural killer cell lines having increased cytotoxicity
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.
Core Innovation
The invention relates to a natural killer (NK) cell or NK cell line modified to reduce function, with respect to a wildtype NK cell or NK cell line, of one or more checkpoint inhibitory receptors. The checkpoint inhibitory receptors include CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT, and TIM-3, and reduced checkpoint inhibitory receptor function is achieved by genetic modification.
The NK cell or NK cell line is further modified to express a mutant TRAIL ligand with increased affinity for TRAIL receptors and/or reduced affinity for decoy TRAIL receptors. The TRAIL receptors include TRAIL death receptors, and the decoy TRAIL receptors include DcR1 and DcR2, and this combined engineering aims to enhance NK cell cytotoxicity in the cancer context.
The document describes engineered NK cell lines and their use in cancer therapy, including derivatives of the KHYG-1 cell line and NK-92. Examples are reported using KHYG-1 derivatives and NK-92, including modifications associated with checkpoint inhibitory receptor reduction and expression of a TRAIL/TRAIL-variant ligand, and the reported results include enhanced apoptosis and cytotoxicity against leukemia and myeloma cell lines.
Claims Coverage
The relevant independent claims cover engineered NK cells or NK cell lines with reduced checkpoint inhibitory receptor function combined with expression of a mutant TRAIL ligand. Across the independent claims, the main inventive coverage includes four inventive elements: reduced checkpoint inhibitory receptor function, mutant TRAIL ligand with altered receptor/decoy affinity, optional species/line constraints, and use for treating cancer in an individual.
Checkpoint inhibitory receptor function reduction plus mutant TRAIL ligand
An NK cell or NK cell line modified to have reduced function, with respect to a wildtype NK cell or NK cell line, of one or more checkpoint inhibitory receptors, and further modified to express a mutant TRAIL ligand with an increased affinity for TRAIL receptors and/or a reduced affinity for decoy TRAIL receptors.
KHYG-1 derivative NK cell line with reduced checkpoint inhibitory receptors and mutant TRAIL ligand
An NK cell line modified to have reduced function, with respect to a wildtype NK cell line, of one or more checkpoint inhibitory receptors, further modified to express a mutant TRAIL ligand with an increased affinity for TRAIL receptors and/or a reduced affinity for decoy TRAIL receptors, and being a derivative of the KHYG-1 cell line.
Genetic knockout of CD96 (TACTILE) and/or CD328 (SIGLEC7) in human NK cells
A human natural killer (NK) cell or NK cell line genetically modified, with respect to a wildtype NK cell or NK cell line, by knocking out a gene for a checkpoint inhibitory receptor selected from CD96 (TACTILE) and CD328 (SIGLEC7).
Cancer treatment by administering engineered NK cells with reduced checkpoint inhibition and mutant TRAIL ligand
A method of treating a cancer in an individual in need thereof, comprising administering to the individual an NK cell or NK cell line modified to have reduced function of one or more checkpoint inhibitory receptors and further modified to express a mutant TRAIL ligand with increased affinity for TRAIL receptors and/or reduced affinity for decoy TRAIL receptors.
KHYG-1 derivative NK cell line administration for cancer treatment
A method of treating a cancer in an individual in need thereof, comprising administering to the individual an NK cell line modified to have reduced function of one or more checkpoint inhibitory receptors, further modified to express a mutant TRAIL ligand with increased affinity for TRAIL receptors and/or reduced affinity for decoy TRAIL receptors, and being a derivative of the KHYG-1 cell line.
Across the independent claims, coverage centers on engineered NK cells or NK cell lines combining reduced checkpoint inhibitory receptor function with expression of a mutant TRAIL ligand engineered for increased affinity for TRAIL receptors and/or reduced affinity for decoy TRAIL receptors. The independent claim set further includes human cell embodiments, genetic knockout of checkpoint inhibitory receptor genes, KHYG-1 derivative NK cell line embodiments, and methods for treating cancer by administering the engineered NK cells or NK cell lines.
Stated Advantages
Enhanced apoptosis and cytotoxicity against leukemia and myeloma cell lines.
Documented Applications
Treating a cancer in an individual in need thereof by administering an NK cell or NK cell line modified to reduce function of one or more checkpoint inhibitory receptors and to express a mutant TRAIL ligand.
Treating blood cancer by administering the human NK cell or NK cell line of the described genetic knockout configuration to an individual.
Interested in licensing this patent?